CELUW - Celularity Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

0.0500

-0.0129

(-20.51%)

As of 02:30PM EDT. Market open.

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	0.0629
Open	1.2300
Bid	1.0200 x 1400
Ask	1.1900 x 1800
Day's Range	0.0496 - 0.0720
52 Week Range	0.0496 - 0.0720
Volume	139,188
Avg. Volume	N/A

Market Cap	N/A
Beta (5Y Monthly)	0.21
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8700
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CELUW

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

GlobeNewswire
Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability
Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improve the safety of ASC-based cell therapy FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic
PR Newswire
CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS
Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has received a $45 million purchase order for its private label Halal-Certified biomaterial products from Jamjoom Medical Store (Jamjoom).This marks the first purchase order received by Celularity under its recently announced expansion into the Middle East market, as part of Celularity's global market strategy.
GlobeNewswire
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity’s Halal-Certified Biomaterial Products
Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and clinical and investigational stage cellular therapeutic programsMarks an important first step in Celularity’s expansion strategy into the Middle East with a priority focus on the Gulf region, according to Celularity CEO, Dr. Robert Hariri.Celularity biomaterial products are manufactured in its state-of-the-art cGMP/cGTP compliant facility located in Florham Park, New Jersey
GlobeNewswire
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
Early-stage data presented at the 26th Annual Meeting of the American Society for Gene and Cell Therapy demonstrate that therapy with placental-derived mesenchymal-like adherent stem cells (MLASCs) results in alterations in gene and protein signatures associated with inflammation and fistula formation in patients with Crohn’s disease Celularity continues to investigate its novel MLASC candidate, APPL-01, in Crohn’s disease FLORHAM PARK, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nas
GlobeNewswire
Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products
Celularity has been advised by the Tamer Group to expect at least $60 million to $80 million in 2023 purchase orders for Celularity's branded Halal-Certified biomaterial products Tamer Group is the exclusive distributor of Celularity's branded Halal-Certified biomaterial products in the Kingdom of Saudi Arabia Issuance of purchase orders conditioned upon receipt of regulatory approvals and other customary conditions precedent FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (
GlobeNewswire
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
Data will be presented demonstrating that therapy with placental-derived mesenchymal-like adherent stem cells (MLASC) results in alterations in gene and protein signatures associated with inflammation and fistula formation in patients with Crohn’s disease who responded to Celularity’s MLASC treatmentFLORHAM PARK, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial prod
GlobeNewswire
Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia
In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001 cells per dose, two of four patients achieved an objective response at Day 28 In patients with measurable residual disease-positive (MRD positive) AML treated with a three-dose regimen consisting of 1.8 billion CYNK-001 cells per dose, one of three patients achieved MRD negativity Treatment with CYNK-001 was generally well-tolerated, with no observed dose-limi
GlobeNewswire
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”
Hariri, Celularity’s CEO, Chairman and Founder, will open the meeting with the keynote address highlighting recent progress and important next steps for the science of longevity together with Scott Gottlieb, M.D., Senior Fellow of the American Enterprise Institute and former Commissioner of the U.S. Food and Drug Administration FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell
GlobeNewswire
Celularity Inc. Announces $6 Million Registered Direct Offering
FLORHAM PARK, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 9,230,770 shares of its Class A common stock together with warrants to purchase up to 9,230,770 shares of its Class A common stock at a combine
GlobeNewswire
Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting
FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA. The oral presentation and poster highlights the role decellularized dehydrated human amniotic membranes plays in support
GlobeNewswire
Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health
Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of the product Celularity intends to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH) in early 2024 Today’s FUSE and February’s Investigational Celularity Tendon Wrap Regulatory Updates, Coupled with Celularity’s Growing Middle East Distribution Agreements, Highlight Celularity’s Suite of Innovative Biomaterial Products FLORH
PR Newswire
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt
Celularity Inc. (Nasdaq: CELU) ("Celularity"), a biotechnology company developing placental-derived allogenic cell therapies and biomaterial products announces that it has entered into an exclusive distribution agreement with AD Ports Logistics (ADPL), a subsidiary of the Logistics Cluster, AD Ports Group, the leading global facilitator of trade, logistics and industry based in Abu Dhabi (ADPORTS:ADX). In partnership with CH Trading Group LLC ("CH Trading Group"), an international import, export
GlobeNewswire
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt
AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt Product distribution agreement opens access to Celularity’s Halal-Certified regenerative medicines, health and wellness products across the Middle East News follows the previously announced Product Distribution Agreement for the Kingdom of Saudi Arabia FLORHAM PARK, N.J. and RIYADH, Abu Dhabi, March 28, 2023 (GLOBE NEWSWIRE) --
GlobeNewswire
Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH)
Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix Celularity to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH) This press release corrects an error in the second paragraph in which the word “not” was omitted. FLORHAM PARK, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-deri
GlobeNewswire
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH)
Celularity’s Pre-Request for Designation (Pre-RFD) is based on data showing CTW contains 100 percent extracellular matrix Celularity to submit 510(k) pre-market notification to the FDA Center for Devices and Radiological Health (CDRH) FLORHAM PARK, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that, in response to its O
GlobeNewswire
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates
Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for Biomaterial-Cell Therapy Combination Approach FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” the “Company”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial-based regenerative therapeutics products, announced today
PR Newswire
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East
Celularity Inc. (Nasdaq: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement. CH Trading Group will act as the exclusive territories distributor of Celularity's previously announced Halal-Certified products within more than 1
PR Newswire
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia
Celularity Inc. (NASDAQ: CELU) ("Celularity"), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC ("CH Trading Group"), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group ("Tamer"). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity's bra
GlobeNewswire
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support further investigation of novel genetically modified cell therapy in Crohn’s disease FLORHAM PARK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, announced today that its re-analysis of long term follow-up data from
GlobeNewswire
Celularity Appoints Paul Graves as Chief Communications Officer
Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experienceFLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who bri
Business Wire
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model
FLORHAM PARK, N.J., December 05, 2022--Celularity Inc. (Nasdaq: CELU) ("Celularity" or "the "Company"), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, today announced that it received Halal Certification of its business models, commercial stage biomaterial products, and clinical and investigational stage cellular therapeutic programs, indicating that they have undergone rigorous assessment to determine that they are permissi
Business Wire
Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on "The Science and Technology for Extending Healthy Human Lifespan"
FLORHAM PARK, N.J., November 30, 2022--Celularity, Inc. (Nasdaq: CELU) ("Celularity" or "the Company"), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, shared today that Chairperson, Founder and Chief Executive Officer Robert J. Hariri, M.D., Ph.D. addressed the Future Investment Initiative 6th Edition in Riyadh conference sponsored by the Future Investment Initiative (FII) at the plenary session: The Science and Technology f
GlobeNewswire
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic
GlobeNewswire
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancerAppointed Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer and announced the promotion of two senior executives and the formation of a new Executive CommitteePresenting an abstract at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting that supports the scientific rationale of the CYNK-101Strengthened bala
GlobeNewswire
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it will present preclinical data on the development of its novel placental-derived allogeneic genetically modified natural killer (NK) cell therapy program CYNK-101 in combination with avelumab. Celularity will report its findings in a poster presentation at t